Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Inclusion Criteria: 1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing; 2. Age ≥ 6 years; 3. Has residual tumor or minor disease progression following standard therapy, and has no available effective treatment option. (\*: Prior to vaccine administration, during the vaccine manufacturing period, continuation of the prior antitumor regimen is permitted in combination with the study drug(s).) 4. Expected survival time greater than 6 months; 5. ECOG performance status score of 0-1; - Exclusion Criteria: * 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.